Study on BMX-001 for Reducing Mouth Sores in Head and Neck Cancer Patients

This study explores if the drug BMX-001 can reduce painful mouth sores in patients undergoing chemoradiation therapy for head and neck cancer. By comparing it to a placebo, researchers aim to see if BMX-001 offers additional relief.

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck and disruptive p53 mutations who have undergone surgery.

This study may be approprate for those with:Newly Diagnosed Cancer

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations. Participants will choose to undergo surgery to remove the fallopian tubes only and plan to have the ovaries removed in the future (BLS group) or remove the fallopian tubes and ovaries at the same time (BSO group).

This study may be approprate for those with:Newly Diagnosed Cancer

Study on Petosemtamab for Treated Head and Neck Cancer

This study tests Petosemtamab versus other treatments chosen by doctors on previously treated head and neck cancer patients. Its goal is to see if Petosemtamab improves outcomes for these patients.

This study may be approprate for those with:Recurrent

Blood Test for ctDNA in Guiding Immunotherapy After Bladder Cancer Surgery

This study is testing if a blood test that checks for DNA from bladder cancer cells can guide the use of immunotherapy after surgery. It aims to find out if this approach can help prevent the cancer from coming back. The study will involve patients who have had bladder cancer surgery and will look at how well additional treatments work based on the blood test results.

This study may be approprate for those with:Newly Diagnosed Cancer

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)

Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone

This study may be approprate for those with:Metastatic Cancer

ZEN003694 with Capecitabine for Advanced Solid Tumors

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment.

This study may be approprate for those with:Metastatic Cancer

Evaluating Safety of ABBV-525 in B-Cell Cancer Treatments

This study is testing a new drug, ABBV-525, for safety and effectiveness in treating certain B-cell cancers. Participants will receive different doses to see how the drug affects their disease and overall health. The study will take place over several months with regular visits to medical centers.

This study may be approprate for those with:Relapsed / Refractory

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer.

This study may be approprate for those with:Newly Diagnosed Cancer

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with genomic alterations.

This study may be approprate for those with:Metastatic Cancer

Trial of BNT113 and Pembrolizumab for HPV16+ Head and Neck Cancer

This study looks into a new treatment approach using BNT113 and pembrolizumab for head and neck cancer linked to HPV16. Patients' safety, response rates, and overall survival will be compared between those getting the combined treatment versus standard pembrolizumab treatment alone.

This study may be approprate for those with:Metastatic Cancer

Adding SNDX-5613 to the Standard Chemotherapy Treatment for Newly Diagnosed Patients With Acute Myeloid Leukemia

This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene.

This study may be approprate for those with:Newly Diagnosed Cancer

Comparing Anitocabtagene Autoleucel to Standard Therapy for Multiple Myeloma

This study compares a new drug, anitocabtagene autoleucel, with standard treatments for multiple myeloma that's difficult to treat. Participants need to have tried 1-3 other treatments previously. The study aims to see if the new drug is better at stopping the disease from getting worse.

This study may be approprate for those with:Relapsed / Refractory

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

This study may be approprate for those with:Metastatic Cancer

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)

The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C.

This study may be approprate for those with:Newly Diagnosed Cancer

Study on UB-VV111 and Rapamycin for CD19+ B-cell Malignancies

This study tests a new treatment, UB-VV111, with or without Rapamycin in patients with certain returning B-cell cancers. It evaluates the safety and how well the treatment works over two years. Eligible participants must meet specific health criteria. Pregnant women and people with certain conditions cannot join.

This study may be approprate for those with:Relapsed / Refractory

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/​M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer.

This study may be approprate for those with:Metastatic Cancer

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).

This study may be approprate for those with:Newly Diagnosed Cancer

Bevacizumab with or without Mirvetuximab in Ovarian, Fallopian Tube, or Peritoneal Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

This study may be approprate for those with:Recurrent

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003)

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

This study may be approprate for those with:Newly Diagnosed Cancer

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

This study may be approprate for those with:Newly Diagnosed Cancer

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/​11 Mutations or PRKC Fusions

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.

This study may be approprate for those with:Metastatic Cancer

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC.

This study may be approprate for those with:Relapsed / Refractory

Letrozole Study in Recurrent High Grade Gliomas

Gliomas- Letrozole+Standard Therapy

This study may be approprate for those with:Recurrent

Study on TEV-56278 for Treating Advanced Solid Tumors

This study tests the safety and effectiveness of TEV-56278, alone and with Pembrolizumab, in advanced solid tumors treatment. Participants will be involved for up to two years, receiving treatment and undergoing monitoring to assess drug safety and any anti-tumor activity.

This study may be approprate for those with:Metastatic Cancer

Study on IOV-4001 for Advanced Melanoma and NSCLC

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

This study may be approprate for those with:Metastatic Cancer

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma.

This study may be approprate for those with:Newly Diagnosed Cancer

Study of PF-07934040 for Advanced Tumors with KRAS Gene Mutations

This study tests a new cancer drug, PF-07934040, for people with advanced tumors having KRAS mutations. Participants will take this drug alone or with other therapies to see its safety and effectiveness. The study lasts up to four years, with regular clinic visits.

This study may be approprate for those with:Relapsed / Refractory

Early Signatures of Vascular aging in Women with Breast Cancer

This is a pilot study where breast cancer patients and healthy controls are randomized to one of two types of exercise interventions and have blood samples collected to detect early signatures of vascular aging.

This study may be approprate for those with:Newly Diagnosed Cancer

Testing the Addition of the Drug Apalutamide to Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery.

This study may be approprate for those with:Newly Diagnosed Cancer

Trial for New Glioblastoma Treatment with Added Lomustine

This study tests if adding lomustine to usual therapy helps treat a specific type of brain cancer better. Participants will be randomly assigned treatment groups to compare effects on survival and tumor progression.

This study may be approprate for those with:Newly Diagnosed Cancer

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation (REDEL)

To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.

This study may be approprate for those with:Newly Diagnosed Cancer

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

This clinical trial, sponsored by Poseida Therapeutics, is an open-label, Phase 1 study evaluating the safety of P-CD19CD20-ALLO1 CAR-T cells in adults with certain relapsed or refractory B cell malignancies. The study involves dose escalation to find a safe dosage and examines the treatment's safety and effectiveness over time. Participants will undergo lymphodepletion therapy before receiving the CAR-T cells. The trial aims to measure safety, adverse events, and responses to treatment, including survival rates and progression-free survival.

This study may be approprate for those with:Relapsed / Refractory

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. 

This study may be approprate for those with:Newly Diagnosed Cancer

Comparing Dostarlimab vs Placebo After Chemoradiation for Head and Neck Cancer

This study tests if Dostarlimab helps prevent cancer from returning or spreading in patients with advanced head and neck cancer after chemoradiation. Participants must be newly diagnosed without distant cancer spread. It lasts up to 5 years.

This study may be approprate for those with:Newly Diagnosed Cancer

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3)

TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. 

This study may be approprate for those with:Metastatic Cancer

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome

This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts.

This study may be approprate for those with:Newly Diagnosed Cancer

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.

This study may be approprate for those with:Newly Diagnosed Cancer

Selinexor for Maintenance in Advanced Endometrial Cancer

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy.

This study may be approprate for those with:Relapsed / Refractory

A Phase 1/​2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

This clinical trial is investigating the drug MRTX0902 for treating advanced solid tumors with specific mutations. The study is in Phase 1/2 and is currently recruiting participants. It aims to evaluate the safety, tolerability, and effectiveness of MRTX0902, both alone and in combination with another drug, adagrasib. The trial includes patients with cancers like non-small cell lung cancer and colorectal cancer who have certain genetic mutations. Participants must have tumors that can't be surgically removed and have no other treatment options.

This study may be approprate for those with:Metastatic Cancer

Testing Abemaciclib with 5-Fluorouracil for Metastatic Colorectal Cancer

This study tests a new combination of cancer drugs for people with advanced colorectal cancer that hasn't responded to other treatments. It aims to find a safe dose that can be tolerated by most patients while seeing if the drug combo is effective in treating the cancer.

This study may be approprate for those with:Metastatic Cancer

Study on Treatment Combinations for Advanced Lung Cancer

This study is testing how well certain drug combinations work against advanced lung cancer with specific genetic mutations. Two different combinations are being tested: one is a mix of two drugs, amivantamab and lazertinib, and the other is amivantamab with chemotherapy. The study hopes to control cancer growth and improve survival.

This study may be approprate for those with:Metastatic Cancer

Study of IMPT-314 in R/​R Aggressive B-cell NHL

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy.

This study may be approprate for those with:Relapsed / Refractory

Study of Selinexor and Temozolomide for Recurrent Brain Tumors

This study tests if combining a new drug, selinexor, with usual chemotherapy can better treat recurrent brain tumors than chemotherapy alone.

This study may be approprate for those with:Recurrent

Comparing Effectiveness of Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).

Testing New Drug Combo for Treating Acute Myeloid Leukemia

This study tests if a combination of three drugs can safely treat newly diagnosed AML patients. Researchers seek to find the safest dose and see how well this drug combo helps fight leukemia.

This study may be approprate for those with:Recurrent

Comparing ABBV-383 to Standard Treatments in Relapsed Multiple Myeloma

This study will compare a new medicine, ABBV-383, to current treatments for people with relapsed multiple myeloma, aiming to provide better management and outcomes for the disease.

This study may be approprate for those with:Relapsed / Refractory

XmAb808 and Pembrolizumab Study in Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.

This study may be approprate for those with:Metastatic Cancer

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

This study may be approprate for those with:Metastatic Cancer

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma.

This study may be approprate for those with:Newly Diagnosed Cancer

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?

This study may be approprate for those with:Newly Diagnosed Cancer

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Pembro or Observation

This study may be approprate for those with:Newly Diagnosed Cancer

A Study of DB-1311 in Advanced/​Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.

This study may be approprate for those with:Metastatic Cancer

Study of ZE50-0134 for Chronic Lymphocytic Leukemia and Lymphomas

This study tests ZE50-0134 in adults with certain blood cancers like chronic lymphocytic leukemia that have not responded to standard treatments. Researchers aim to find a safe dose level and evaluate effectiveness over several weeks through different stages of testing. Participants should not have certain serious health conditions.

This study may be approprate for those with:Relapsed / Refractory

Study of RAS Inhibitors in GI Tumors

This study evaluates new RAS inhibitors combined with standard or new treatments for patients with gastrointestinal cancers, including colorectal and pancreatic cancers. The focus is on safety, tolerability, and early antitumor effects. The study has three parts, each testing different drug combinations. Participants must be adults with certain cancer types and meet health criteria. Outcomes include monitoring adverse events, drug levels, and patient responses over time.

This study may be approprate for those with:Metastatic Cancer

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable).

This study may be approprate for those with:Newly Diagnosed Cancer

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

This study will be conducted in two parts: a dose finding portion to determine the maximum tolerated dose and recommended phase 2 dose (RP2D) of TOS-358 administered orally on once a day (QD) and twice daily (BID) schedules, and a dose expansion portion to evaluate safety and tolerability in tumor-specific cohorts administered TOS-358 at the recommended phase 2 dose and schedule.

This study may be approprate for those with:Metastatic Cancer

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

This study may be approprate for those with:Metastatic Cancer

Study on New Treatment for Recurrent Ovarian Cancer

This study tests a new drug for ovarian cancer that has returned. It compares the new treatment's safety and effectiveness with standard care to see if patients live longer without their disease getting worse. Patients will be closely monitored for side effects.

This study may be approprate for those with:Relapsed / Refractory

Testing Venetoclax for Relapsed Hairy Cell Leukemia

This study examines whether venetoclax is effective in treating patients with relapsed hairy cell leukemia. It involves taking the medication daily and regular check-ups for up to 19 cycles.

This study may be approprate for those with:Relapsed / Refractory

Evaluating Safety and Efficacy of ABBV-101 for B-Cell Malignancies

The study evaluates a new drug, ABBV-101, for adults with certain B-cell cancers. It examines safety, effectiveness, and the movement of ABBV-101 through the body over about five years. Participants will have regular hospital visits for monitoring and tests.

This study may be approprate for those with:Relapsed / Refractory

A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.

This study may be approprate for those with:Newly Diagnosed Cancer

A Study of NX-5948 in Adults With Relapsed/​Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.

This study may be approprate for those with:Relapsed / Refractory

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.

This study may be approprate for those with:Relapsed / Refractory

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)

This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic).

This study may be approprate for those with:Newly Diagnosed Cancer

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)

This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.

This study may be approprate for those with:Metastatic Cancer

Testing RMC-6236 for Metastatic Pancreatic Cancer Treatment

This Phase 3 study tests RMC-6236 against standard chemotherapy in patients with metastatic pancreatic cancer who have already received treatment. It aims to see if the new drug improves survival rates and delays disease progression. Participants need to be 18 years or older and meet certain health criteria.

This study may be approprate for those with:Metastatic Cancer

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/​3rd/​4th Salvage

Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment

This study may be approprate for those with:Relapsed / Refractory

Comparing Two Radiation Therapies for Brain Cancer Spread from Other Body Parts

This study examines whether a longer duration of radiation therapy (called FSRS) is better than the usual shorter therapy (SRS) for people with certain cancers that have spread to the brain. It involves comparing how well each method works in preventing cancer from growing and the side effects experienced.

This study may be approprate for those with:Relapsed / Refractory

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

This study may be approprate for those with:Relapsed / Refractory

Study of AJ1-11095 for Untreatable Myelofibrosis Patients

This study tests the safety and effectiveness of a new drug, AJ1-11095, on myelofibrosis patients who haven't responded to previous treatments. Participants will receive the drug to find out the safest dose.

This study may be approprate for those with:Relapsed / Refractory

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

This study may be approprate for those with:Newly Diagnosed Cancer

Study of V940 Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer

This study aims to compare the effectiveness of V940 plus pembrolizumab versus a placebo plus pembrolizumab in treating patients with certain stages of lung cancer that have been surgically removed. Key outcomes include time until cancer recurrence, overall survival, and quality of life. Participants must have had complete tumor removal and prior chemotherapy. The study will follow participants for up to 12 years to monitor these outcomes.

This study may be approprate for those with:Newly Diagnosed Cancer

OBI-3424 in Relapsed T-ALL: Phase II Trial Study

This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory).

This study may be approprate for those with:Relapsed / Refractory

A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors

This clinical trial is a Phase I study to evaluate the safety and tolerability of onCARlytics (CF33-CD19) combined with blinatumomab in adults with advanced or metastatic solid tumors. It involves both intravenous and intratumoral administration of the treatment. The study is recruiting participants who have advanced solid tumors that have progressed after at least two prior treatments for their cancer.

This study may be approprate for those with:Metastatic Cancer

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

This study may be approprate for those with:Newly Diagnosed Cancer

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. 

This study may be approprate for those with:Recurrent

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell)

This study may be approprate for those with:Newly Diagnosed Cancer

Study on ABBV-383 for Relapsed or Refractory Multiple Myeloma

This study tests ABBV-383, a drug for relapsed/refractory multiple myeloma, focusing on safety and side effects. About 180 people will participate globally, receiving the drug by IV every 28 days for up to three years, with regular check-ups.

This study may be approprate for those with:Relapsed / Refractory

ECOG ACRIN

This clinical trial, conducted by the National Cancer Institute, is testing treatments for adults newly diagnosed with BCR-ABL-positive acute lymphoblastic leukemia. It compares the effects of standard chemotherapy and steroids with a tyrosine kinase inhibitor (TKI) to the same regimen plus blinatumomab, a drug that may help stop cancer cell growth. The study aims to determine if the combination therapy improves overall survival and reduces residual disease. It also assesses the side effects and outcomes for patients who undergo different treatment paths. The trial is currently recruiting. Participants must be 18 to 75 years old and meet specific health criteria.

This study may be approprate for those with:Newly Diagnosed Cancer

Study of Rilvegostomig vs. Pembrolizumab with Chemotherapy for Lung Cancer

This study compares rilvegostomig against pembrolizumab when taken with chemotherapy for treating advanced squamous NSCLC in patients whose tumors express PD-L1.

This study may be approprate for those with:Metastatic Cancer

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable).

This study may be approprate for those with:Metastatic Cancer

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK)

This study may be approprate for those with:Newly Diagnosed Cancer

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Hormonal Agents

AZD5305 + (NHAs) (enzalutamide, abiraterone, or darolutamide

This study may be approprate for those with:Recurrent

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.

This study may be approprate for those with:Newly Diagnosed Cancer

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/​PD-L1 Inhibitors (PRESERVE-003)

The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy.

This study may be approprate for those with:Metastatic Cancer

A Study of LP-118 in Patients With Advanced Tumors

This is a phase I, multi-center, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-118 in patients with advanced malignancies, including solid tumors and lymphomas. LP-118 is a BCL-2/BCL-XL small molecule inhibitor.

This study may be approprate for those with:Relapsed / Refractory

Testing CHS-114 in People with Advanced Solid Tumors

This study is testing a new treatment, CHS-114, for people with difficult-to-treat solid tumors. It checks if the treatment is safe and helpful and looks at how patients respond. There are three parts: testing different doses of the treatment, saw about its effects alone, and combined with another drug.

This study may be approprate for those with:Relapsed / Refractory

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE)

This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable).

This study may be approprate for those with:Newly Diagnosed Cancer

Testing FDA-Approved Drugs for Tumor Gene Abnormalities in Cancer

This study aims to test FDA-approved drugs on patients with advanced stage cancers that have specific gene abnormalities. Participants must have a type of cancer not responsive to standard treatment and will help researchers learn about the effectiveness and safety of these treatments. The study will last up to 3 years and requires regular visits for monitoring.

Testing the Addition of BMS-986016 (Relatlimab) to Immunotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

This clinical trial, led by the National Cancer Institute, is studying the addition of the drug relatlimab to the usual immunotherapy treatment for patients with recurrent or metastatic nasopharyngeal cancer. The trial aims to see if adding relatlimab to nivolumab can improve the time patients live without their cancer getting worse. Participants receive initial treatment with chemotherapy and immunotherapy, then are randomized to continue with nivolumab alone or with the addition of relatlimab.

This study may be approprate for those with:Recurrent

Study of Toripalimab With Chemotherapy for Nasopharyngeal Cancer

This study tests if a drug combo, including toripalimab, helps treat certain advanced nasopharyngeal cancers. Participants should not have had similar treatments before or foreign growths that are curable with other treatments. Researchers will assess benefits like tumor shrinkage.

This study may be approprate for those with:Metastatic Cancer

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.

This study may be approprate for those with:Metastatic Cancer

Low-Dose Tamoxifen for Early-Stage Breast Cancer Study

This research compares a low dose of tamoxifen with standard hormone therapies to treat early-stage breast cancer in post-menopausal women, checking if it's as effective in preventing recurrence.

This study may be approprate for those with:Newly Diagnosed Cancer

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

This study may be approprate for those with:Metastatic Cancer

A Phase 1B/​2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies (ARTACUS)

This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients.

This study may be approprate for those with:Metastatic Cancer

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

This study may be approprate for those with:Relapsed / Refractory

Amivantamab in Adenoid Cystic Carcinoma

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

This study may be approprate for those with:Metastatic Cancer

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.

This study may be approprate for those with:Relapsed / Refractory

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. 

This study may be approprate for those with:Newly Diagnosed Cancer

Pembrolizumab Study for Non-Small Cell Lung Cancer Treatment

This study is examining if adding the drug V940 to pembrolizumab helps prevent non-small cell lung cancer from returning after surgery. Participants must meet specific health criteria and cannot have certain prior treatments or conditions. The research will assess various health outcomes like survival and quality of life over a period that could last up to about 129 months.

This study may be approprate for those with:Recurrent

Study of Ipatasertib with Chemoradiation for Head and Neck Cancer

This study investigates whether adding ipatasertib to standard chemo-radiation improves treatment outcomes for head and neck cancer. The goal is to find a safe dose that might offer better cancer control than existing therapies alone.

This study may be approprate for those with:Newly Diagnosed Cancer

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced).

This study may be approprate for those with:Metastatic Cancer

Pancreatic Ductal- Met or unrectable

Gemcitabine/ Nab-Paclitaxel + CA-4948, must have had prior 5FU based therapy

This study may be approprate for those with:Metastatic Cancer

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/​R NHL or CLL

This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a Dose Escalation Phase (Part 1) and a Dose Expansion Phase (Part 2)

This study may be approprate for those with:Relapsed / Refractory

Study of MK-1084 and Pembrolizumab for Lung Cancer

This study explores the combination of MK-1084 and pembrolizumab for treating a specific type of lung cancer. It checks if this duo is better than current options by increasing survival rates and slowing cancer progression.

This study may be approprate for those with:Newly Diagnosed Cancer

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.

This study may be approprate for those with:Metastatic Cancer

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer

This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy.

This study may be approprate for those with:Relapsed / Refractory

Testing New Treatment for Residual Cancer in B-cell Lymphoma Patients

This study tests a new treatment called cema-cel for adults with large B-cell lymphoma who show minimal residual disease after initial therapy. It aims to compare this treatment's effectiveness and safety against standard observation post-treatment.

This study may be approprate for those with:Newly Diagnosed Cancer

Safety and Efficacy of REGN7075 and Cemiplimab in Cancer

This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. 

This study may be approprate for those with:Metastatic Cancer

Study of DF9001 in Patients With Advanced Solid Tumors

DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). A combination therapy cohort will be opened for enrollment, DF9001 + nivolumab. The second phase will include a dose expansion using the best dose selected from the first phase of the study.

This study may be approprate for those with:Metastatic Cancer

Study of Cemiplimab and Surgery for Advanced Skin Cancer

This study evaluates whether adding the immunotherapy drug cemiplimab to surgery improves treatment outcomes for patients with advanced, resectable skin cancer.

This study may be approprate for those with:Metastatic Cancer

Combining Iadademstat with Immunotherapy for Advanced Lung Cancer

Researchers are studying whether adding a new drug, iadademstat, to existing immunotherapies can better control small cell lung cancer. The study involves repeated cycles of treatment and aims to find out if this combination can keep the cancer stable longer than current treatments alone.

This study may be approprate for those with:Newly Diagnosed Cancer

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) who are ineligible to receive cisplatin-based chemoradiation concurrently.

This study may be approprate for those with:Newly Diagnosed Cancer

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

This study may be approprate for those with:Recurrent

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

This study may be approprate for those with:Relapsed / Refractory